The **PREFER Study** aims to understand cancer better by collecting **biological samples** like blood and tissue from patients with advanced cancer. These samples will be compared using two methods: liquid biopsy (blood test) and next generation sequencing (a detailed lab test). This helps find important changes in cancer cells, called **driver mutations**.

The study focuses on different types of advanced cancers such as lung, breast, gastrointestinal, and others. The goal is to use personalized medicine, which means finding the right treatment for each person based on their cancer type. This is especially important for minority and underserved communities.

The study will create a **biorepository**, a collection of samples and data for future research. This helps scientists develop new medicines and understand cancer better. Participants will give permission for their samples to be used in future drug development.

• **Eligibility**: Patients must be 18+, recently diagnosed, and able to give consent.
• **Duration**: Participation involves regular follow-ups, but no extra invasive tests.
• **Risks/Compensation**: No extra risks; samples are collected during standard care.